Evidence map›Paper›PMID 36180740›Full record

ArticleCellular and molecular life sciences : CMLS2022

p73 is required for vessel integrity controlling endothelial junctional dynamics through Angiomotin.

Laura Maeso-Alonso, Hugo Alonso-Olivares, Nicole Martínez-García, Lorena López-Ferreras, Javier Villoch-Fernández, Laura Puente-Santamaría, Natalia Colas-Algora, Alfonso Fernández-Corona, María Elena Lorenzo-Marcos, Benilde Jiménez and 7 more

Open access · hybridAbstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Role of angiomotin family members in human diseases (Review).Experimental and therapeutic medicine · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 2 countries.

Laura Maeso-AlonsoInstituto de Biomedicina y Departamento de Biología Molecular, Universidad de León, 24071, León, Spain.
Hugo Alonso-OlivaresInstituto de Biomedicina y Departamento de Biología Molecular, Universidad de León, 24071, León, Spain.
Nicole Martínez-GarcíaInstituto de Biomedicina y Departamento de Producción Animal, Universidad de León, 24071, León, Spain.
Lorena López-FerrerasInstituto de Biomedicina y Departamento de Biología Molecular, Universidad de León, 24071, León, Spain.
Javier Villoch-FernándezInstituto de Biomedicina y Departamento de Biología Molecular, Universidad de León, 24071, León, Spain.
Laura Puente-SantamaríaDepartamento de Bioquímica, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), Madrid, Spain.
Natalia Colas-AlgoraCentro de Biología Molecular "Severo Ochoa" (CSIC-UAM), Madrid, Spain.
Alfonso Fernández-CoronaComplejo Asistencial Universitario de León, León, Spain.
María Elena Lorenzo-MarcosComplejo Asistencial Universitario de León, León, Spain.
Benilde JiménezDepartamento de Bioquímica, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), Madrid, Spain.
Lars HolmgrenDepartment of Oncology-Pathology, Bioclinicum, Karolinska Institutet, 17164, Stockholm, Sweden.
Margareta WilhelmDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 171 65, Stockholm, Sweden.
Jaime MillanCentro de Biología Molecular "Severo Ochoa" (CSIC-UAM), Madrid, Spain.
Luis Del PesoDepartamento de Bioquímica, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), Madrid, Spain.
Lena Claesson-WelshDepartment of Immunology, Genetics and Pathology, Rudbeck Laboratory, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Margarita M MarquesInstituto de Desarrollo Ganadero y Sanidad Animal, y Departamento de Producción Animal, Universidad de León, 24071, León, Spain.
Maria C MarinInstituto de Biomedicina y Departamento de Biología Molecular, Universidad de León, 24071, León, Spain. mmarv@unileon.es.ORCID http://orcid.org/0000-0002-7149-287X
Universidad de León · ESCentro de Biología Molecular Severo Ochoa · ESComplejo Asistencial Universitario de Palencia · ESHospital Universitario La Paz · ESKarolinska Institutet · SEInstituto de Ganadería de Montaña · ESInstituto de Investigaciones Biomédicas Sols-Morreale · ESUppsala University · SE

Funding

Junta de Castilla y León LE022P20Ministerio de Ciencia e Innovación PID2019-105169RB-I00
6 · The paper itself

Abstract

Preservation of blood vessel integrity, which is critical for normal physiology and organ function, is controlled at multiple levels, including endothelial junctions. However, the mechanism that controls the adequate assembly of endothelial cell junctions is not fully defined. Here, we uncover TAp73 transcription factor as a vascular architect that orchestrates transcriptional programs involved in cell junction establishment and developmental blood vessel morphogenesis and identify Angiomotin (AMOT) as a TAp73 direct transcriptional target. Knockdown of p73 in endothelial cells not only results in decreased Angiomotin expression and localization at intercellular junctions, but also affects its downstream function regarding Yes-associated protein (YAP) cytoplasmic sequestration upon cell-cell contact. Analysis of adherens junctional morphology after p73-knockdown in human endothelial cells revealed striking alterations, particularly a sharp increase in serrated junctions and actin bundles appearing as stress fibers, both features associated with enhanced barrier permeability. In turn, stabilization of Angiomotin levels rescued those junctional defects, confirming that TAp73 controls endothelial junction dynamics, at least in part, through the regulation of Angiomotin. The observed defects in monolayer integrity were linked to hyperpermeability and reduced transendothelial electric resistance. Moreover, p73-knockout retinas showed a defective sprout morphology coupled with hemorrhages, highlighting the physiological relevance of p73 regulation in the maintenance of vessel integrity in vivo. We propose a new model in which TAp73 acts as a vascular architect integrating transcriptional programs that will impinge with Angiomotin/YAP signaling to maintain junctional dynamics and integrity, while balancing endothelial cell rearrangements in angiogenic vessels.

Indexed as

AngiomotinsEndothelial CellsActinsCadherinsHumansIntercellular JunctionsTranscription FactorsYAP-Signaling ProteinsActinsAngiomotinsCadherinsTranscription FactorsYAP-Signaling ProteinsActin cytoskeletonCell junctionsEndothelial barrier integrityp53 familyVascular morphogenesisVE-cadherin and angiogenesis

Identifiers

PMID36180740
PMCPMC9525397
OpenAlexW4298120912

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.